Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform

Immunai, a New York-based biotech company, today announced a $215M Series B, increasing the company’s total funding to date to $295M. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.